CORCEPT THERAPEUTICS INC 8-K

What Happened

• On January 22, 2026, Corcept Therapeutics, Inc. filed a Form 8‑K and issued a press release (attached as Exhibit 99.1) announcing that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab‑paclitaxel for patients with platinum‑resistant ovarian cancer, met its overall survival primary endpoint.

Key Details

• Date filed: January 22, 2026; press release attached as Exhibit 99.1 and incorporated by reference.
• Trial: ROSELLA — a pivotal Phase 3 study.
• Treatment/Indication: relacorilant in combination with nab‑paclitaxel for platinum‑resistant ovarian cancer.
• Primary endpoint: overall survival was met (the 8‑K attaches the announcement but does not include detailed survival figures or statistical data).

Why It Matters

• Meeting a Phase 3 overall survival primary endpoint is a major clinical milestone. For investors, this is material news because it can affect regulatory strategy and the clinical value of Corcept’s relacorilant program.
• The 8‑K itself provides the announcement but not the full data or next steps; investors should look for the company’s full data release and any regulatory filings or guidance that follow.